Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (DE:0RA)
FRANKFURT:0RA
Holding DE:0RA?
Track your performance easily
0RA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.81 - €24.20
Previous Close€1.58
Volume0.00
Average Volume (3M)N/A
Market Cap
€53.32M
Enterprise Value-€35.68M
Total Cash (Recent Filing)$97.91M
Total Debt (Recent Filing)$5.12M
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Mar 06, 2025EPS Estimate
-€0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,958,253
10 Day Avg. Volume25
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
€5.79Price Target Upside266.59% Upside
Rating ConsensusHold
Number of Analyst Covering5
RAPT Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial Strength And Pipeline DevelopmentRAPT announced a $150 million private placement to shore up capital resources and fund their new clinical plans.
Licensing And Market PotentialRAPT gaining worldwide development and commercialization rights to RPT904, excluding mainland China, Hong Kong, and Macau, represents a constructive step forward for their broader immunology pipeline.
Product Differentiation And Market OpportunityRPT904 shares the same binding epitope with Xolair but with greater binding affinity and a longer half-life, suggesting a multibillion dollar market opportunity.
Bears Say
Financial UncertaintyUncertainty around next-gen compound development likely necessitates a capital raise.
Program TerminationThe recent termination of the Zelnecirnon program has led to a downgrade of RAPT to Hold.
Regulatory SetbacksFDA's feedback is a setback for RAPT's near-term efforts in autoimmune disease development.
---
Options Prices
Currently, No data available
---
Ownership Overview
6.10% Insiders
23.95% Mutual Funds
25.11% Other Institutional Investors
38.64% Public Companies and
Individual Investors
0RA FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was €0.81 and its highest was €24.20 in the past 12 months.
What is RAPT Therapeutics’s market cap?
Currently, no data Available
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 62 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Nov 12, 2024. The company reported -€0.454 earnings per share for the quarter, beating the consensus estimate of -€0.56 by €0.106.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -€0.31.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 34,958,252 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -€0.454 in its last earnings report, beating expectations of -€0.56. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Among the largest hedge funds holding RAPT Therapeutics’s share is Woodline Partners LP. It holds RAPT Therapeutics’s shares valued at 476K.
---
RAPT Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€5.79 (266.59% Upside)
€5.79 (266.59% Upside)
Blogger Sentiment
Bullish
DE:0RA Sentiment 66%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.64%
12-Months-Change
Fundamentals
Return on Equity
-80.13%
Trailing 12-Months
Asset Growth
-45.69%
Trailing 12-Months
Company Description
RAPT Therapeutics
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
---
0RA Stock 12 Month Forecast
Average Price Target
€5.79
▲(266.59% Upside)
Technical Analysis
RAPT Therapeutics
―
Immunocore Holdings
―
Kura Oncology
―
Blueprint Medicines
―
Fate Therapeutics
―
Best Analysts Covering 0RA
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-28.11%
downgraded a sell rating 2 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -28.11% per trade.
---